From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies?

Area of Science:

• Oncology
• Pharmacology
• Genomics

Background:

• Precision oncology has advanced cancer care through small molecule drugs targeting somatic genomic alterations.
• Concerns exist regarding declining pharmaceutical investment in small molecule drugs and tyrosine kinase inhibitors (TKIs).
• Factors contributing to this trend include market saturation, drug resistance, economic challenges, and regulatory impacts like the Inflation Reduction Act (IRA).

Purpose of the Study:

• To highlight the critical role of small molecule drugs in precision oncology.
• To identify the challenges hindering the development of novel small molecule oncology drugs.
• To propose strategies for revitalizing innovation and investment in this field.

Main Methods:

• Literature review and analysis of current trends in pharmaceutical research and development.
• Examination of economic and regulatory factors impacting drug development incentives.
• Assessment of barriers to patient access to genomic testing.

Main Results:

• Small molecule drugs and TKIs have shown significant patient benefits in precision cancer medicine.
• Pharmaceutical industry focus is shifting away from small molecule development.
• Patient access to comprehensive genomic testing remains a significant hurdle.

Conclusions:

• A multifaceted approach is essential to reverse the declining trend in small molecule oncology drug development.
• Key strategies include embracing new technologies, fostering collaborations, regulatory innovation, and improving patient access to genomic testing.
• Sustained investment and stakeholder collaboration are crucial for advancing personalized medicine and improving patient outcomes.